Shares in AstraZeneca rose past their September 2024 peak on Tuesday, hitting a fresh record high and cementing the company's ...

The combined rate of heart attack, stroke, bleeding complications or death was 16.6% in the ticagrelor group and 14.2% in the ...

Britain's FTSE 100 closed at a record high for the second straight session on Tuesday, as weak UK labour market data boosted ...

AstraZeneca and Sun Pharma will jointly market SZC, a key hyperkalaemia drug for CKD and heart failure patients, under ...

Under the agreement, AstraZeneca will sell SZC under the brand Lokelma, while Sun Pharma will distribute it as Gimliand.

AstraZeneca will market the therapy as Lokelma, while Sun Pharma will promote and distribute it as Gimliand. AstraZeneca will ...

Good news from the laboratory put some zip into AstraZeneca (NASDAQ: AZN) shares on Monday. The veteran pharmaceutical ...

The pharmaceutical company posted a 14% on-year increase in third-quarter core earnings per share, while revenue rose to ...

AstraZeneca's aldosterone synthase inhibitor baxdrostat reduced blood pressure by 14 mmHg over 12 weeks, the pharma has said ...

AstraZeneca is the stock to beat in the United Kingdom. The global pharmaceutical company saw its stock rise to its all-time ...

In an investor call Thursday, AstraZeneca CEO Pascal Soriot outlined his company’s approach to obesity drug development based ...

AstraZeneca's Baxdrostat cut blood pressure by 14 mmHg in the Phase 3 Bax24 trial, showing strong efficacy and safety in resistant hypertension patients.